Rock Springs Capital Reduces Agios Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy AGIO?
Source: Fool
- Share Reduction Details: Rock Springs Capital Management disclosed the sale of 159,379 shares of Agios Pharmaceuticals in Q4 2026, with an estimated transaction value of $5.59 million, indicating a decline in confidence towards the company.
- Position Value Change: As of Q4 2026, Rock Springs' position in Agios was valued at $21.75 million, down $16.72 million from the previous quarter, reflecting negative market sentiment and trading activity impacting the stock.
- Market Performance Analysis: Agios shares were priced at $27.96 as of February 16, 2026, down 16% over the past year and trailing the S&P 500 by 27.8 percentage points, indicating challenges in its competitive position within the biotechnology sector.
- Investor Focus: Despite the reduction in holdings, the FDA approved AQVESME for adult anemia treatment in December 2026, highlighting Agios' potential in rare diseases, prompting investors to monitor future clinical developments closely.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 28.530
Low
25.00
Averages
36.14
High
62.00
Current: 28.530
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
- Drug Approval: Agios Pharmaceuticals' PYRUKYND (mitapivat) has been approved by the Emirates Drug Establishment, becoming the only treatment option for adults with non-transfusion-dependent and transfusion-dependent thalassemia in the UAE, marking a significant breakthrough in treatment options.
- Clinical Trial Support: This approval is based on results from the global randomized double-blind ENERGIZE and ENERGIZE-T Phase 3 trials, demonstrating that PYRUKYND can effectively improve hemoglobin levels in patients, addressing the urgent need for innovative therapies in the region.
- Market Potential: With approximately 70,000 individuals affected by thalassemia in the Gulf region, the launch of PYRUKYND is expected to significantly enhance patients' quality of life and provide strong support for Agios's expansion in this market.
- Commercial Partnership: Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to advance regulatory filings and commercialization of PYRUKYND in the Gulf Cooperation Council, further solidifying its strategic position in the Middle East and North Africa market.
See More
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
- Share Sale Details: Commodore Capital disclosed in a SEC filing that it sold all 2,338,287 shares of Agios Pharmaceuticals in Q4 2026, amounting to approximately $93.86 million, indicating a significant loss of confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Agios shares were priced at $27.82, down 17% over the past year, significantly underperforming the S&P 500's roughly 13% gain, reflecting market concerns about its future prospects.
- Financial Overview: Agios Pharmaceuticals has a market capitalization of $1.63 billion, with a trailing twelve-month revenue of $54.03 million and a net loss of $412.78 million, highlighting substantial challenges in achieving profitability.
- Investor Focus: In the biotech sector, capital is shifting towards momentum-driven companies, and Agios's poor performance in clinical trials has led to a sharp stock decline, prompting investors to prioritize execution over mere asset options.
See More
Rock Springs Capital Reduces Agios Holdings
- Share Reduction Details: Rock Springs Capital Management disclosed the sale of 159,379 shares of Agios Pharmaceuticals in Q4 2026, with an estimated transaction value of $5.59 million, indicating a decline in confidence towards the company.
- Position Value Change: As of Q4 2026, Rock Springs' position in Agios was valued at $21.75 million, down $16.72 million from the previous quarter, reflecting negative market sentiment and trading activity impacting the stock.
- Market Performance Analysis: Agios shares were priced at $27.96 as of February 16, 2026, down 16% over the past year and trailing the S&P 500 by 27.8 percentage points, indicating challenges in its competitive position within the biotechnology sector.
- Investor Focus: Despite the reduction in holdings, the FDA approved AQVESME for adult anemia treatment in December 2026, highlighting Agios' potential in rare diseases, prompting investors to monitor future clinical developments closely.
See More
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
- AQVESME Launch Strategy: CEO Brian Goff emphasized that Agios will focus on executing a high-impact launch of AQVESME for thalassemia treatment in the U.S. in 2026, which is expected to enhance the company's market share and lay the groundwork for future expansions.
- PYRUKYND Revenue Growth: In Q4 2025, PYRUKYND net revenue reached $20 million, reflecting an impressive 86% year-on-year growth, indicating the effectiveness of the company's commercialization strategy in the PK deficiency market, with projected revenues of $45 million to $50 million in 2026.
- Strong Financial Position: Agios ended 2025 with approximately $1.2 billion in cash and cash equivalents, providing flexibility for the AQVESME launch and other R&D projects, showcasing the company's confidence and capability in future investments.
- Optimistic Market Outlook: Management expressed optimism regarding early market response for AQVESME, with 44 prescriptions written by REMS-certified physicians as of January 30, reflecting strong recognition of clinical value and expected to drive future revenue growth.
See More
Agios Pharmaceuticals Reports Q4 2025 Earnings and FDA Approval
- Earnings Report: Agios Pharmaceuticals reported a FY GAAP EPS of -$7.12, missing estimates by $0.06, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $54.03 million, a 48.1% year-over-year increase, exceeding market expectations by $7.91 million, suggesting strong product sales and market demand that could lay the groundwork for future growth.
- FDA Drug Approval: Agios' AQVESME (mitapivat) received FDA approval for treating anemia in adults with alpha and beta thalassemia, marking a significant advancement in the company's blood disorder treatment portfolio, potentially driving future sales growth.
- Investor Conference: Agios presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially attracting more investment and partnership opportunities.
See More
Agios Pharmaceuticals Reports Key 2025 Financial Highlights
- Significant Revenue Growth: In Q4 2025, net revenues for PYRUKYND® (mitapivat) reached $16 million in the U.S., representing a 49% increase from Q4 2024, reflecting the company's sustained commercial focus in the PK deficiency space and a strong launch of AQVESME™ (mitapivat) in the thalassemia market.
- FDA Approval of New Drug: AQVESME™ received FDA approval in December 2025 as the only medication for treating anemia in adults with non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance the company's market share and brand influence in this area.
- R&D Progress on Track: Agios has fully enrolled its Phase 2 trial of tebapivat for sickle cell disease, with topline results expected in the second half of 2026, laying a solid foundation for further development in this therapeutic area.
- Strong Financial Position: As of December 31, 2025, the company reported $1.2 billion in cash, cash equivalents, and marketable securities, which, despite a decrease from 2024, remains sufficient to support the U.S. commercial launch of AQVESME and advance other clinical programs.
See More
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
- Drug Approval: Agios Pharmaceuticals' PYRUKYND (mitapivat) has been approved by the Emirates Drug Establishment, becoming the only treatment option for adults with non-transfusion-dependent and transfusion-dependent thalassemia in the UAE, marking a significant breakthrough in treatment options.
- Clinical Trial Support: This approval is based on results from the global randomized double-blind ENERGIZE and ENERGIZE-T Phase 3 trials, demonstrating that PYRUKYND can effectively improve hemoglobin levels in patients, addressing the urgent need for innovative therapies in the region.
- Market Potential: With approximately 70,000 individuals affected by thalassemia in the Gulf region, the launch of PYRUKYND is expected to significantly enhance patients' quality of life and provide strong support for Agios's expansion in this market.
- Commercial Partnership: Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to advance regulatory filings and commercialization of PYRUKYND in the Gulf Cooperation Council, further solidifying its strategic position in the Middle East and North Africa market.
See More
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
- Share Sale Details: Commodore Capital disclosed in a SEC filing that it sold all 2,338,287 shares of Agios Pharmaceuticals in Q4 2026, amounting to approximately $93.86 million, indicating a significant loss of confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Agios shares were priced at $27.82, down 17% over the past year, significantly underperforming the S&P 500's roughly 13% gain, reflecting market concerns about its future prospects.
- Financial Overview: Agios Pharmaceuticals has a market capitalization of $1.63 billion, with a trailing twelve-month revenue of $54.03 million and a net loss of $412.78 million, highlighting substantial challenges in achieving profitability.
- Investor Focus: In the biotech sector, capital is shifting towards momentum-driven companies, and Agios's poor performance in clinical trials has led to a sharp stock decline, prompting investors to prioritize execution over mere asset options.
See More
Rock Springs Capital Reduces Agios Holdings
- Share Reduction Details: Rock Springs Capital Management disclosed the sale of 159,379 shares of Agios Pharmaceuticals in Q4 2026, with an estimated transaction value of $5.59 million, indicating a decline in confidence towards the company.
- Position Value Change: As of Q4 2026, Rock Springs' position in Agios was valued at $21.75 million, down $16.72 million from the previous quarter, reflecting negative market sentiment and trading activity impacting the stock.
- Market Performance Analysis: Agios shares were priced at $27.96 as of February 16, 2026, down 16% over the past year and trailing the S&P 500 by 27.8 percentage points, indicating challenges in its competitive position within the biotechnology sector.
- Investor Focus: Despite the reduction in holdings, the FDA approved AQVESME for adult anemia treatment in December 2026, highlighting Agios' potential in rare diseases, prompting investors to monitor future clinical developments closely.
See More
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
- AQVESME Launch Strategy: CEO Brian Goff emphasized that Agios will focus on executing a high-impact launch of AQVESME for thalassemia treatment in the U.S. in 2026, which is expected to enhance the company's market share and lay the groundwork for future expansions.
- PYRUKYND Revenue Growth: In Q4 2025, PYRUKYND net revenue reached $20 million, reflecting an impressive 86% year-on-year growth, indicating the effectiveness of the company's commercialization strategy in the PK deficiency market, with projected revenues of $45 million to $50 million in 2026.
- Strong Financial Position: Agios ended 2025 with approximately $1.2 billion in cash and cash equivalents, providing flexibility for the AQVESME launch and other R&D projects, showcasing the company's confidence and capability in future investments.
- Optimistic Market Outlook: Management expressed optimism regarding early market response for AQVESME, with 44 prescriptions written by REMS-certified physicians as of January 30, reflecting strong recognition of clinical value and expected to drive future revenue growth.
See More
Agios Pharmaceuticals Reports Q4 2025 Earnings and FDA Approval
- Earnings Report: Agios Pharmaceuticals reported a FY GAAP EPS of -$7.12, missing estimates by $0.06, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $54.03 million, a 48.1% year-over-year increase, exceeding market expectations by $7.91 million, suggesting strong product sales and market demand that could lay the groundwork for future growth.
- FDA Drug Approval: Agios' AQVESME (mitapivat) received FDA approval for treating anemia in adults with alpha and beta thalassemia, marking a significant advancement in the company's blood disorder treatment portfolio, potentially driving future sales growth.
- Investor Conference: Agios presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially attracting more investment and partnership opportunities.
See More
Agios Pharmaceuticals Reports Key 2025 Financial Highlights
- Significant Revenue Growth: In Q4 2025, net revenues for PYRUKYND® (mitapivat) reached $16 million in the U.S., representing a 49% increase from Q4 2024, reflecting the company's sustained commercial focus in the PK deficiency space and a strong launch of AQVESME™ (mitapivat) in the thalassemia market.
- FDA Approval of New Drug: AQVESME™ received FDA approval in December 2025 as the only medication for treating anemia in adults with non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance the company's market share and brand influence in this area.
- R&D Progress on Track: Agios has fully enrolled its Phase 2 trial of tebapivat for sickle cell disease, with topline results expected in the second half of 2026, laying a solid foundation for further development in this therapeutic area.
- Strong Financial Position: As of December 31, 2025, the company reported $1.2 billion in cash, cash equivalents, and marketable securities, which, despite a decrease from 2024, remains sufficient to support the U.S. commercial launch of AQVESME and advance other clinical programs.
See More
